Drugging the p53 pathway: understanding the route to clinical efficacy
The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …
Exploiting replicative stress to treat cancer
M Dobbelstein, CS Sørensen - Nature reviews Drug discovery, 2015 - nature.com
DNA replication in cancer cells is accompanied by stalling and collapse of the replication
fork and signalling in response to DNA damage and/or premature mitosis; these processes …
fork and signalling in response to DNA damage and/or premature mitosis; these processes …
[HTML][HTML] Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
MV Blagosklonny - Oncotarget, 2023 - ncbi.nlm.nih.gov
Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells.
Paradoxically, cancer resistance to certain therapies can be exploited for protection of …
Paradoxically, cancer resistance to certain therapies can be exploited for protection of …
Dying to survive—the p53 paradox
A Lees, T Sessler, S McDade - Cancers, 2021 - mdpi.com
Simple Summary p53 is best known for its tumour suppressive functions mediated through
regulation of an extensive-gene regulatory network. Here we review progress in our …
regulation of an extensive-gene regulatory network. Here we review progress in our …
[HTML][HTML] Molecular mechanisms underlying curcumin-mediated microRNA regulation in carcinogenesis; Focused on gastrointestinal cancers
Curcumin is a bioactive ingredient found in the Rhizomes of Curcuma longa. Curcumin is
well known for its chemopreventive and anti-cancer properties. Recent findings have …
well known for its chemopreventive and anti-cancer properties. Recent findings have …
Bifunctional ligand design for modulating mutant p53 aggregation in cancer
JJ Miller, A Blanchet, C Orvain, L Nouchikian… - Chemical …, 2019 - pubs.rsc.org
Protein misfolding and aggregation contributes to the development of a wide range of
diseases. In cancer, over 50% of diagnoses are attributed to p53 malfunction due to …
diseases. In cancer, over 50% of diagnoses are attributed to p53 malfunction due to …
p53-Based cyclotherapy: exploiting the 'guardian of the genome'to protect normal cells from cytotoxic therapy
B Rao, S Lain, AM Thompson - British journal of cancer, 2013 - nature.com
Side effects of chemotherapy are a major impediment in the treatment of cancer.
Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side …
Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side …
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells
G Lodi, V Gentili, F Casciano, A Romani… - Frontiers in …, 2022 - frontiersin.org
SARS-CoV viruses have been shown to downregulate cellular events that control antiviral
defenses. They adopt several strategies to silence p53, key molecule for cell homeostasis …
defenses. They adopt several strategies to silence p53, key molecule for cell homeostasis …
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
KA Urtishak, LS Wang, B Culjkovic-Kraljacic… - Oncogene, 2019 - nature.com
The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new
treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and …
treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and …
Persistence to anti-cancer treatments in the stationary to proliferating transition
The heterogeneous responses of clonal cancer cells to treatment is understood to be
caused by several factors, including stochasticity, cell-cycle dynamics, and different micro …
caused by several factors, including stochasticity, cell-cycle dynamics, and different micro …